Format

Send to

Choose Destination
Blood Cancer J. 2014 Sep 5;4:244. doi: 10.1038/bcj.2014.64.

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

Author information

1
Amgen Research (Munich) GmbH, Munich, Germany.
2
1] Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.
3
Amgen Inc., Thousand Oaks, CA, USA.
4
Medical Department III, University Ulm, Ulm, Germany.
5
Medical Department II, City Hospital and University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
6
Bone Marrow Transplantation Center, University Münster, Münster, Germany.
7
Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.
8
Metronomia GmbH, Munich, Germany.
9
Center of Internal Medicine, J.W. Goethe University, Frankfurt, Germany.
PMID:
25192414
PMCID:
PMC4183773
DOI:
10.1038/bcj.2014.64
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center